Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid

被引：0
|
作者：
Kridin, Khalaf [1 ,2 ,3 ]
Hammers, Christoph M. [1 ,4 ]
机构：
[1] Univ Lubeck, Lubeck Inst Expt Dermatol LIED, Lubeck, Germany
[2] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel
[3] Barch Padeh Med Ctr, Unit Dermatol & Skin Res Lab, Poriya, Israel
[4] Christian Albrechts Univ Kiel, Dept Dermatol, Kiel, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 06期
关键词：
D O I：
10.1111/bjd.21882
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：843 / 844
页数：2
相关论文
共 50 条
  • [1] Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma
    Hansen, Inga
    Gebhardt, Christoffer
    Booken, Nina
    Schneider, Stefan W.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 (04): : 587 - 589
  • [2] Enriched class II HLA inherence in patients with checkpoint inhibitor-associated bullous pemphigoid
    Gandarillas, Sophia
    Berger, Adam
    Stephenson, Ryan
    Mehregan, Darius
    Dasgeb, Bahar
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024,
  • [3] Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity
    Guo, Xiaoxiao
    Wang, Hanping
    Zhou, Jiaxin
    Li, Yue
    Duan, Lian
    Si, Xiaoyan
    Zhang, Li
    Fang, Ligang
    Zhang, Li
    THORACIC CANCER, 2020, 11 (02) : 475 - 480
  • [4] Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
    Tasanen, Kaisa
    Varpuluoma, Outi
    Nishie, Wataru
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [5] Extensive erosive bullous pemphigoid: an atypical and serious clinical variant
    Cordel, N
    Courville, P
    Martel, P
    Musette, P
    Joly, P
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (03) : 537 - 539
  • [6] Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid
    Muramatsu, Ken
    Zheng, Miao
    Yoshimoto, Norihiro
    Ito, Takamasa
    Ujiie, Inkin
    Iwata, Hiroaki
    Shimizu, Hiroshi
    Ujiie, Hideyuki
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2020, 100 (01) : 23 - 30
  • [7] DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient
    Usami, Jun
    Takezawa, Yumiko
    INTERNAL MEDICINE, 2020, 59 (04) : 593 - 593
  • [8] Exacerbation of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid by the immune checkpoint inhibitors durvalumab and tremelimumab
    Inoue, Shinichiro
    Mai, Yosuke
    Youh, Joohyung
    Shimano, Mayuna
    Hikichi, Shiori
    Kosumi, Hideyuki
    Ujiie, Inkin
    Izumi, Kentaro
    Usami, Makoto
    Ujiie, Hideyuki
    JOURNAL OF DERMATOLOGY, 2025,
  • [9] Esophageal involvement in DPP4 inhibitor-associated bullous pemphigoid
    Brufau-Cochs, Magi
    Alamon-Reig, Francesc
    Luque-Luna, Mar
    Bosch-Amate, Xavier
    Moreta, Maria Jose
    Bassegoda, Octavi
    Mascaro Jr, Jose M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 (03): : 432 - 433
  • [10] Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid
    Bellinato, Francesco
    Maurelli, Martina
    Schena, Donatella
    Gisondi, Paolo
    Girolomoni, Giampiero
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2021, 156 (04) : 455 - 459
12345